Research Article

Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in Japan

Hidenaga Kawasumi,1 Takahisa Gono,1 Yasushi Kawaguchi,1 Masataka Kuwana,2 Hirotaka Kaneko,1 Yasuhiro Katsumata,1 Sayuri Kataoka,1 Masanori Hanaoka,1 and Hisashi Yamanaka 1

1Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan
2Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan

Correspondence should be addressed to Takahisa Gono; tgono@ior.twmu.ac.jp

Received 8 October 2015; Accepted 31 December 2015

Academic Editor: Marzia Caproni

Copyright © 2016 Hidenaga Kawasumi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The physical function of PM/DM patients after remission induction therapy remains unknown adequately. The aim of our study was to evaluate the present status of physical dysfunction and to clarify the clinical manifestations and myositis-specific autoantibodies (MSAs) associated with physical dysfunction after treatment in PM/DM.

Methods. We obtained clinical data including the age at disease onset, gender, disease duration, laboratory data prior to initial treatment, and the specific treatment administered. We evaluated disease activity and physical dysfunction after treatment using the core set provided by the International Myositis Assessment and Clinical Studies Group.

Results. 57% of the 77 enrolled patients with PM/DM had trouble in daily living even after their disease activity was adequately controlled. In a multivariate analysis, the age at disease onset, female gender, and CK levels before treatment were significantly associated with the severity of physical dysfunction after treatment. Anti-SRP positivity was associated with more severe physical dysfunction after treatment than anti-ARS or anti-MDA5.

Conclusions. Half of the PM/DM patients showed physical dysfunction after treatment. Age at disease onset, gender, CK level before treatment, and anti-SRP were significant predictors associated with physical dysfunction after treatment in PM/DM.

1. Introduction

Polymyositis (PM) and dermatomyositis (DM) are idiopathic inflammatory myopathies that occasionally present with extramuscular lesions such as interstitial lung disease (ILD) [1, 2], cardiomyopathy [3], and malignancy [4]. Some PM/DM patients still suffer from muscle weakness and physical dysfunction after remission induction therapies [5]. As a result, these patients have trouble with daily living even after their disease activity is adequately controlled. Sustained physical dysfunction after treatment may be associated with the PM/DM disease duration, irreversible muscle damage, and the adverse effects of corticosteroids such as myopathy, vertebral compression fracture, and avascular necrosis [5, 6].

Recent PM/DM therapeutic strategies have improved the overall survival prognosis of patients [6–8]. In addition, several myositis-specific autoantibodies (MSAs) have been identified and are useful for predicting clinical manifestations, treatment outcomes, and vital prognoses [9–11]. For example, patients with anti-Mi-2 antibodies more commonly develop DM, and these patients are less likely to develop ILD or malignancy [12–14]. Moreover, the treatment outcomes of anti-Mi-2-positive patients are relatively better than those with other autoantibodies. In contrast, patients
with anti-signal recognition particle (SRP) antibodies often
develop necrotising myopathy, which is refractory to corti-
costeroid therapy, and a tapering dosage of corticosteroids
often causes a recurrence of the myositis [15–21]. However,
the physical function outcomes of PM/DM patients after
remission remain poorly characterised. Moreover, the pre-
dictive factors of physical dysfunction following treatment
among PM/DM patients remain unknown.

In the present study, we evaluated the present status of
physical dysfunction in PM/DM outpatients after treatment.
Moreover, we identified clinical manifestations and MSAs
that are associated with physical dysfunction after treatment.

2. Patients and Methods

2.1. Patients. Among the PM/DM outpatients who regularly
visited our hospital from August to October 2013, informed
consent was obtained from seventy-seven outpatients. These
77 PM/DM patients were enrolled in the present study. Some
of the included patients also had clinically amyopathic DM
(CADM). All of these patients were previously admitted
to our hospital to receive remission induction therapy for
PM/DM. At the time of admission, all patients had not
received remission induction therapy yet. The diagnoses of
PM, DM, or CADM were made based on the criteria of Bohan
and Peter [22] or those of Sontheimer [23].

We obtained clinical data from the medical records of all
the enrolled patients. These clinical data included the age at
disease onset, gender, disease duration, laboratory data prior
to initial treatment (e.g., plasma creatinine kinase (CK),
lactate dehydrogenase (LDH), and C-reactive protein (CRP)
levels), extramuscular lesions (ILD, cardiomyopathy, and
malignant disease), the specific treatment administered, and
the occurrence of relapse. This study was approved by the
Ethical Committee of Tokyo Women's Medical University
according to the Declaration of Helsinki.

2.2. Evaluation of Serum Myositis-Specific Autoantibodies
and Myositis-Associated Autoantibodies. Serum samples were
obtained from 67 patients on admission and were stored at
−80°C. In the other 10 patients, the serum samples were not
stored and could not be evaluated. We evaluated the positivity
of MSAs and myositis-associated autoantibodies (MAAs).
Anti-a minoacyl-tRNA synthetase (anti-ARS), anti-SRP, anti-
Ku, and anti-SS-A antibodies were evaluated using an immu-
noprecipitation assay. Anti-melanoma differentiation-
associated gene 5 (anti-MDA5) antibodies were measured
with an enzyme-linked immunosorbent assay. Anti-transcrip-
tional intermediary factor 1-γ (anti-TIF1-γ), anti-Mi-2, and
anti-nuclear matrix protein-2 (anti-NXP-2) antibodies were
detected using western blot. Anti-U1RNP antibodies were
measured using an Ouchterlony double immunodiffusion
assay.

2.3. Evaluation of Disease Activity and Physical Function. We
evaluated the disease activity, muscle strength, and physical
function of each patient one time after treatment from August
to October 2013 in our outpatient ward. Disease activity was
evaluated using the myositis disease activity core set pro-
vided by the International Myositis Assessment and Clinical
Studies (IMACS) Group [24, 25]. The disease activities were
evaluated by the patients (the Patient Global Assessment
(PGA)) and the physicians (the Evaluator's Global Assess-
ment (EGA)) on a 0–100-point scale. In the present study,
we defined the presence of disease activity as PGA or EGA
scores greater than 10 points. Muscle strength was evaluated
using the manual muscle test for eight muscles (MMT8)
using a 0–10-point scale [26]. We evaluated the severity of
physical function using the Japanese version of the Health
Assessment Questionnaire Disability Index (J-HAQ-DI) [27].
The Stanford HAQ is a self-report questionnaire assessing
physical function pertaining to the activities of daily living
[28]. The J-HAQ was adapted directly from the Stanford HAQ
and was first published in 2003 [27]; this instrument was
translated into Japanese with culturally appropriate modifica-
tions. Although the J-HAQ was originally developed for use
in rheumatoid arthritis, it has been applied to a variety of
rheumatic conditions in Japan. In the present study, physical
dysfunction was defined as a J-HAQ-DI score greater than 0.5
[29].

2.4. Statistical Analysis. Statistical analyses were performed
using the Mann-Whitney U test to compare median values.
The correlation coefficients were established by Spearman's
correlation coefficient. The multivariate analysis was per-
formed using multiple regression analysis. The data were
analysed using JMP® software (SAS Institute, NC, USA). P
values <0.05 indicated statistical significance.

3. Results

3.1. Clinical Characteristics of the Enrolled Patients. As shown
in Table 1, 77 patients were enrolled in this study. The
median age at disease onset was 46 years, and 79% of the
patients were female. The numbers of PM, DM, and CADM
cases were 40, 30, and 7, respectively. The median time
between disease onset and starting treatment was 3 months.
In addition, the median time between disease onset and the
J-HAQ evaluation was 105 months. ILD, cardiomyopathy,
and malignancy were found in 52 (68%), 13 (17%), and 3
(4%) patients, respectively. In regard to MSAs, anti-ARS,
anti-MDA5, anti-Mi-2, anti-NXP-2, anti-SRP, and anti-TIF1-
γ antibodies were detected in 22 (29%), 7 (9%), 2 (3%), 2 (3%),
9 (12%), and 4 (5%) patients, respectively. Disease relapse
occurred in 30 (39%) patients.

3.2. Severity of Physical Dysfunction and Disease Activity in
PM/DM Patients. Figure 1(a) presents the cumulative prob-
ability of physical dysfunction among the enrolled patients.
The J-HAQ-DI score was greater than 0 and 0.5 in 57% and
30% of the patients, respectively. As shown in Figure 1(b),
disease activity evaluated by patients was revealed in 60% of
patients. In contrast, disease activity evaluated by physicians
was revealed in 20% of patients (Figure 1(c)).

3.3. Associations between Physical Dysfunction and Dis-
ease Activity. Figure 2(a) presents the association between
Table 1: Clinical characteristics of the enrolled PM/DM patients.

| Characteristic                                      | Value          |
|----------------------------------------------------|----------------|
| Age at disease onset, median years                 | 46 (37–58)     |
| Female, number (%)                                 | 61 (79)        |
| PM, DM, CADM, number                               | 40, 30, 7      |
| Duration from disease onset to initiation of treatment, median months | 3 (2–8)         |
| Duration from disease onset to enrolment in this study, median months | 105 (46–143)   |
| Complications at first visit, number (%)           |                |
| Interstitial lung disease                          | 52 (68)        |
| Cardiomyopathy                                     | 13 (17)        |
| Malignancy                                         | 3 (4)          |
| Myositis-specific autoantibodies, number (%)       |                |
| Anti-ARS                                           | 22 (29)        |
| Anti-MDA5                                          | 7 (9)          |
| Anti-Mi-2                                          | 2 (3)          |
| Anti-NXP-2                                         | 2 (3)          |
| Anti-SRP                                           | 9 (12)         |
| Anti-TIF1-γ                                        | 4 (5)          |
| Myositis-associated autoantibodies, number (%)     |                |
| Anti-Ku                                            | 3 (4)          |
| Anti-U1-snRNP                                       | 10 (13)        |
| Anti-SS-A                                          | 30 (39)        |
| Treatment                                          |                |
| Initial dosage of PSL, median mg/day               | 50 (40–60)     |
| Administration of immunosuppressant agents, number (%) | 37 (48)       |
| Presence of relapse, number (%)                    | 30 (39)        |

Values represent medians (interquartile range). P values <0.05.

PM: polymyositis; DM: dermatomyositis; CADM: clinically amyopathic dermatomyositis; ARS: aminoacyl-tRNA synthetase; MDA5: melanoma differentiation-associated gene 5; NXP-2: nuclear matrix protein-2; SRP: signal recognition particle; TIF1-γ: transcriptional intermediary factor 1-γ; PSL: prednisolone.

the J-HAQ-DI and MMT8 assessments. Physical dysfunction was significantly correlated ($r_s = 0.50, P < 0.001$) with muscle weakness. In addition, the severity of physical dysfunction was significantly correlated ($r_s = 0.63, P < 0.0001$) with the PGA results (Figure 2(b)). In contrast, the association between physical dysfunction and EGA results was weakly significant ($r_s = 0.24, P = 0.04$).

3.4. Clinical Manifestations Associated with Physical Dysfunction after Treatment. As shown in Table 2, we conducted a multivariate analysis to identify the clinical factors and complications associated with physical dysfunction after treatment in PM/DM patients. Physical dysfunction was defined as a J-HAQ-DI score of more than 0.5 [29]. Multivariate analysis found that age at disease onset (odds ratio (OR) = 1.07, $P = 0.003$), female gender (OR = 13.6, $P = 0.0075$), and CK levels before treatment (OR = 1.0006, $P = 0.019$) were significantly associated with physical dysfunction after treatment.

3.5. A Comparison of Autoantibodies between Patients with Normal and Dysfunctional Physical Functioning. To identify whether MSAs or MAAs are associated with physical dysfunction after treatment, we compared the positivity rates of each autoantibody between patients with normal and dysfunctional physical functioning. As shown in Table 3, the positivity rate for anti-SRP antibodies was significantly higher ($P = 0.02$) in the dysfunctional patients compared to normal patients. In contrast, the presence of anti-MDA5 antibodies was associated with normal physical function after treatment, although the relationship was not statistically significant.

Figure 3 presents a comparison of the J-HAQ-DI and MMT8 scores between patients with anti-ARS, anti-MDA5, or anti-SRP antibodies. Patients with anti-SRP antibodies showed significantly more severe physical dysfunction and muscle weakness than those with anti-ARS or anti-MDA5 antibodies. The median score of PGA was higher as 44 points in patients with anti-SRP antibodies than those without anti-SRP antibodies as 10 points, although the $P$ value was 0.08, which could not reach statistical significance. In addition, the median score of EGA was less than 5 points in both these subsets. Therefore, these findings indicated that the severity of physical dysfunction could be attributed to disease damage rather than disease activity in myositis. On the other hand, there was no significant difference in the J-HAQ-DI and MMT8 scores between patients with anti-ARS antibodies and those with anti-MDA5 antibodies.
Figure 1: The J-HAQ-DI (a), PGA (b), and EGA (c) scores in enrolled PM/DM patients. Thirty percent of enrolled patients showed physical dysfunction (J-HAQ-DI > 0.5) (a). The PGA (b) and EGA (c) scores were less than 10 in 40% and 80% of patients, respectively. J-HAQ-DI: Japanese version of the Health Assessment Questionnaire Disability Index; PGA: Patient Global Assessment; EGA: Evaluator’s Global Assessment.

4. Discussion

The overall survival prognosis of PM/DM patients has recently improved, although some patients still suffer from physical dysfunction after treatment [5]. There have been few reports in the literature regarding the long-term physical function outcomes of PM/DM patients. Maugars et al. found that approximately 90% of PM/DM patients experienced muscular disability at a 3-year follow-up visit [30]. Ponyi et al. reported that, in 87 PM/DM patients, only 17.5% had no disability, and 12.5% were severely disabled; the remaining patients (70%) were mildly to moderately disabled [31]. In our present study, the median duration between disease onset and the evaluation of physical functioning was 105 months. Approximately 10 years had passed from the onset of PM/DM in most patients enrolled in this study. In 57% of the enrolled patients, the J-HAQ-DI score was greater than 0, which suggests that at least half of PM/DM patients had trouble in daily living activities, even 10 years after remission induction therapy. Thus, PM/DM continues to have a great impact on daily life in the long term.

In the present study, differences were observed between the evaluations of disease activity by patients and physicians. Although it may be difficult for patients to distinguish between irreversible damage and reversible inflammatory symptoms, IMACS defines active inflammation as disease activity. In our study, the age at disease onset, female gender, and CK levels before treatment were significant factors associated with the severity of the J-HAQ-DI scores. Clarke et al. assessed functional status in 257 PM/DM patients and found that physical dysfunction was associated with disease duration [5]. However, in our study, there was not a significant association between the J-HAQ-DI scores and disease duration. The median duration between disease onset and starting treatment was relatively short (3 months) in our patients, which may explain the difference between our findings and those of a previous report. In contrast, the age at disease onset and female gender were associated with physical dysfunction after treatment in the present study. Elderly patients and female patients have less muscle than younger patients and male patients; therefore, even after remission induction treatment, physical dysfunction may be sustained in elderly or female patients. CK serum levels before treatment were also associated with physical dysfunction after treatment in our study. Marie et al. reported that functional disability might be due to the adverse effects of corticosteroids, such
Table 2: Clinical manifestations associated with physical dysfunction in PM/DM patients.

|                          | Odds ratio (95% CI)* | P value |
|--------------------------|----------------------|---------|
| Age at disease onset     | 1.07 (1.02–1.14)     | 0.0030  |
| Female gender            | 13.6 (1.88–168.6)    | 0.0075  |
| Duration from disease onset to the following: |                      |         |
| Initiation of treatment  | 1.01 (0.94–1.13)     | 0.45    |
| Normalisation of CK level| 1.008 (0.92–1.05)    | 0.80    |
| Evaluation of the J-HAQ-DI score | 1.009 (0.99–1.02) | 0.15    |
| Laboratory findings before initial treatment |                      |         |
| CK                       | 1.0006 (1.0001–1.001) | 0.019   |
| LDH                      | 0.99 (0.99–1.005)    | 0.10    |
| CRP                      | 0.87 (0.58–1.14)     | 0.35    |
| Complications            |                      |         |
| ILD                      | 1.28 (0.31–5.60)     | 0.73    |
| Cardiomyopathy           | 3.61 (0.63–22.9)     | 0.15    |
| Malignancy               | 0.07 (0.0008–2.83)   | 0.16    |
| Initial dosage of PSL    | 1.04 (0.98–1.12)     | 0.20    |
| Administration of immunosuppressant agents | 1.23 (0.28–5.45) | 0.78    |
| Presence of relapse      | 1.67 (0.42–6.75)     | 0.46    |

Statistical analyses were performed using multivariate analysis.

* Odds ratio and confidential intervals were calculated per unit.

P values <0.05.

PM: polymyositis; DM: dermatomyositis; CK: creatine kinase; J-HAQ-DI: Japanese version of the Health Assessment Questionnaire Disability Index; LDH: lactate dehydrogenase; CRP: C-reactive protein; ILD: interstitial lung disease; PSL: prednisolone.

Figure 2: Correlations between the J-HAQ-DI score and the MMT8 (a), PGA (b), and EGA (c) scores. The J-HAQ-DI scores were significantly correlated with the MMT8 (a), PGA (b), and EGA (c) scores. Spearman’s rank correlation coefficient (r_s) was used for statistical analysis. J-HAQ-DI: Japanese version of the Health Assessment Questionnaire Disability Index; MMT: manual muscle test; PGA: Patient Global Assessment; EGA: Evaluator’s Global Assessment.
Table 3: A comparison of autoantibody profiles between PM/DM patients with and those without physical dysfunction.

| Physical normal function (n = 46) | Physical dysfunction (n = 21) | P value |
|----------------------------------|-------------------------------|---------|
| **Myositis-specific autoantibodies, number (%)** | | |
| Anti-ARS | 16 (34) | 6 (29) | 0.62 |
| Anti-MDA5 | 7 (15) | 0 (0) | 0.09 |
| Anti-Mi-2 | 1 (2) | 1 (5) | 0.53 |
| Anti-NXP-2 | 2 (4) | 0 (0) | 1.00 |
| Anti-SRP | 3 (7) | 6 (29) | 0.02 |
| Anti-TIF1-γ | 3 (7) | 1 (5) | 0.89 |
| **Myositis-associated autoantibodies, number (%)** | | |
| Anti-Ku | 3 (7) | 0 (0) | 0.55 |
| Anti-U1-snRNP | 6 (13) | 4 (19) | 0.71 |
| Anti-SS-A | 21 (46) | 9 (43) | 1.00 |

Physical dysfunction was defined as a J-HAQ-DI score greater than 0.5. Statistical analyses were performed using the Mann-Whitney U test. P values < 0.05.

PM: polymyositis; DM: dermatomyositis; ARS: aminoacyl-tRNA synthetase; MDA5: melanoma differentiation-associated gene 5; NXP-2: nuclear matrix protein-2; SRP: signal recognition particle; TIF1-γ: transcriptional intermediary factor 1-γ.

Figure 3: Associations between physical dysfunction and MSAs in PM/DM patients. The presence of anti-SRP antibodies was more significantly associated with severe physical dysfunction and muscle weakness after treatment. * P value was less than 0.05. J-HAQ-DI: Japanese version of the Health Assessment Questionnaire Disability Index; ARS: aminoacyl-tRNA synthetase; MDA-5: melanoma differentiation-associated gene 5; SRP: signal recognition particle; MMT: manual muscle test.

as myopathy, osteoporosis, vertebral compression fracture, and avascular necrosis [6]. In our study, the CK levels before treatment may reflect the cumulative dosages of prednisolone (PSL) (the data could not be obtained). Physicians usually check the CK levels and decide whether the dosage of PSL could be tapered. Therefore, patients with lower CK levels before treatment may reach normal CK levels faster than those with higher CK levels and may be treated with smaller cumulative dosages of PSL. In addition, smaller cumulative dosages of PSL are associated with lower risks of the adverse effects of PSL, including steroid myopathy [32].

In the present study, with regard to the associations between MSAs and J-HAQ-DI scores, the presence of anti-SRP antibodies was more significantly associated with severe physical dysfunction after treatment compared to other MSAs (anti-ARS and anti-MDA5). In contrast, anti-MDA5 positivity was more strongly associated with better physical function after treatment compared to other MSAs. As far as we know, the present study is the first to report the association between autoantibodies and functional disability after treatment in PM/DM patients. Anti-SRP-associated myopathy is characterised by necrotising myopathy that is
refractory and relapsing after immunosuppressive therapies. The patients of high CK levels or anti-SRP positive might show high disease activities at the onset of myositis, and their cumulative doses of oral glucocorticoid could be much more. The muscle weakness is caused not only by myositis itself, but also by steroid myopathy [33]. Moreover, our study demonstrated that PGA score was higher in patients with anti-SRP antibodies than others, although there was no difference of EGA score between the two subsets. There was a discrepancy between PGA score and EGA score in patients with anti-SRP antibodies. Therefore, the severity of physical dysfunction after treatment could be attributed to disease damage that resulted from previously active disease or from complications of therapy rather than ongoing disease activity in myositis. On the other hand, patients in East Asia with anti-MDA5 positivity showed complications of dermatitis and rapidly progressive- (RP-) ILD without myositis [9]. In addition, patients with anti-MDA5 antibodies usually show relatively mild dysfunction in daily life after RP-ILD improves, although some patients may succumb to respiratory failure caused by RP-ILD despite immunosuppressive therapies. Therefore, the measurement of MSAs is useful for predicting the physical function outcomes after treatment for PM/DM.

Several limitations of the present study should be considered. First, the patients were retrospectively enrolled. Second, the time between the onset of disease and the evaluation of disease status was different for each patient. In addition, disease status was only evaluated after treatment and not before treatment. Third, sera samples could not be obtained from all enrolled patients. Moreover, patients who died from malignancy, ILD, or other causes could not be included in the present study. Thus, selection bias may have been present in this study.

In conclusion, approximately one-half of PM/DM patients showed difficulties in activities of daily living, even after receiving remission induction therapy. The age at disease onset, gender, CK level before treatments, and anti-SRP positivity were significant factors associated with physical dysfunction after treatment in patients with PM/DM.

Conflict of Interests

The authors have declared no conflict of interests.

Authors’ Contribution

All of the authors were involved in drafting or critically revising the paper to provide important intellectual content, and all of the authors approved the final version to be published. Dr. Takahisa Gono had full access to all of the data in the study, and he takes responsibility for the integrity of the data and the accuracy of the data analysis. Hidenaga Kawasumi, Takahisa Gono, Yasushi Kawaguchi, Yasuhiro Katsumata, and Hisashi Yamanaka contributed to the study conception and design; Hidenaga Kawasumi, Takahisa Gono, Masataka Kuwana, Hirotaka Kaneko, Sayuri Kataoka, and Masanori Hanakoa contributed to the data acquisition; and Hidenaga Kawasumi, Takahisa Gono, and Yasushi Kawaguchi contributed to the data analysis and interpretation.

Acknowledgment

This study was supported in part by research grants from the Ministry of Health, Labor, and Welfare, Japan.

References

[1] H. Kawasumi, T. Gono, Y. Kawaguchi et al., "IL-6, IL-8, and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis/dermatomyositis," BioMed Research International, vol. 2014, Article ID 815245, 6 pages, 2014.
[2] T. Gono, S. Sato, Y. Kawaguchi et al., “Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis,” Rheumatology, vol. 51, no. 9, Article ID kts102, pp. 1563–1570, 2012.
[3] Z. Lu, W. Guo-Chun, M. Li, and Z. Ning, “Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review,” Clinical Cardiology, vol. 35, no. 11, pp. 686–691, 2012.
[4] X. Lu, H. Yang, X. Shu et al., “Factors predicting malignancy in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis,” PLoS ONE, vol. 9, no. 4, Article ID e94128, 2014.
[5] A. E. Clarke, D. A. Bloch, T. A. Medsger Jr., and C. V. Oddis, “A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis,” Arthritis and Rheumatism, vol. 38, no. 9, pp. 1218–1224, 1995.
[6] I. Marie, E. Hachulla, P.-Y. Hatron et al., “Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis,” Journal of Rheumatology, vol. 28, no. 10, pp. 2230–2237, 2001.
[7] S. M. Sultan, Y. Ioannou, K. Moss, and D. A. Isenberg, “Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality,” Rheumatology, vol. 41, no. 1, pp. 22–26, 2002.
[8] K. Dankó, A. Ponyi, T. Constantin, G. Borgulya, and G. Szegedi, “Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases,” Medicine, vol. 83, no. 1, pp. 35–42, 2004.
[9] T. Gono, Y. Kawaguchi, T. Satoh et al., “Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis,” Rheumatology, vol. 49, no. 9, pp. 1713–1719, 2010.
[10] D. F. Fiorentino, K. Kuo, L. Chung, L. Zaba, S. Li, and L. Casciola-Rosen, “Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1 antibodies in adults with dermatomyositis,” Journal of the American Academy of Dermatology, vol. 72, no. 3, pp. 449–455, 2015.
[11] L. Wang, L. Liu, H. Hao et al., “Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients,” Neuromuscular Disorders, vol. 24, no. 4, pp. 335–341, 2014.
[12] G. J. Hengstman, T. M. Vree Egberts, H. P. Seelig et al., “Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2β antigen,” Annals of the Rheumatic Diseases, vol. 65, no. 2, pp. 242–245, 2006.
[13] K. Komura, M. Fujimoto, T. Matsushita et al., “Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis,” *Journal of Dermatological Science*, vol. 40, no. 3, pp. 215–217, 2005.

[14] J.-C. Lega, N. Fabien, Q. Reynaud et al., “The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome,” *Autoimmunity Reviews*, vol. 13, no. 9, pp. 883–891, 2014.

[15] J.-B. Arlet, D. Dimitri, C. Pagnoux et al., “Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP),” *Neuromuscular Disorders*, vol. 16, no. 5, pp. 334–336, 2006.

[16] I. N. Targoff, A. E. Johnson, and F. W. Miller, “Antibody to signal recognition particle in polymyositis,” *Arthritis and Rheumatism*, vol. 33, no. 9, pp. 1361–1370, 1990.

[17] T. Miller, M. Al-Lozi, G. Lopate, and A. Pestronk, “Myopathy with antibodies to the signal recognition particle: clinical and pathological features,” *Journal of Neurology Neurosurgery and Psychiatry*, vol. 73, no. 4, pp. 420–428, 2002.

[18] A. H. Kao, D. Lacomis, M. Lucas, N. Fertig, and C. V. Oddis, “Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy,” *Arthritis and Rheumatism*, vol. 50, no. 1, pp. 209–215, 2004.

[19] G. J. D. Hengstman, H. I. Ter Laak, W. T. M. Vree Egberts et al., “Antibody to signal recognition particle autoantibodies: marker of a necrotising myopathy,” *Annals of the Rheumatic Diseases*, vol. 65, no. 12, pp. 1635–1638, 2006.

[20] T. Takada, M. Hirakata, A. Suwa et al., “Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies,” *Modern Rheumatology*, vol. 19, no. 2, pp. 156–164, 2009.

[21] R. Vályi, L. Casciola-Rosen, G. Hong, A. Mammen, and L. Christopher-Stine, “Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series,” *Arthritis Care and Research*, vol. 62, no. 9, pp. 1328–1334, 2010.

[22] A. Bohan and J. B. Peter, “Polymyositis and dermatomyositis,” *The New England Journal of Medicine*, vol. 292, no. 7, pp. 344–347, 1975.

[23] R. D. Sontheimer, “Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?” *Journal of the American Academy of Dermatology*, vol. 46, no. 4, pp. 626–636, 2002.

[24] L. G. Rider, E. H. Giannini, M. Harris-Love et al., “Defining clinical improvement in adult and juvenile myositis,” *Journal of Rheumatology*, vol. 30, no. 3, pp. 603–617, 2003.

[25] F. W. Miller, L. G. Rider, Y.-L. Chung et al., “Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies,” *Rheumatology*, vol. 40, no. 11, pp. 1262–1273, 2001.

[26] L. G. Rider, D. Koziol, E. H. Giannini et al., “Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies,” *Arthritis Care & Research*, vol. 62, no. 4, pp. 465–472, 2010.

[27] Y. Matsuda, G. Singh, H. Yamanaka et al., “Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis,” *Arthritis Care & Research*, vol. 49, no. 6, pp. 784–788, 2003.